Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
NDC Package Code : 70596-1002
Start Marketing Date : 2021-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
About the Company : EUROAPI is the market leader in small molecule APIs with projected sales of about €1 billion in 2022. With around 200 APIs, it has one of the largest portfolios in the market. Th...
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacture...
About the Company : Sinopep-Allsino Biopharmaceutical Co Ltd.is a biomedical enterprise with the main business of research and development, production, sales and technical services of peptides and sma...
RLD : Yes
TE Code :
Brand Name : LEQVIO
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)
Approval Date : 2021-12-22
Application Number : 214012
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Global Sales Information
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 12
2020 Revenue in Millions : 0
Growth (%) : New Launch in 2021
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 112
2021 Revenue in Millions : 12
Growth (%) : 833
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 355
2022 Revenue in Millions : 112
Growth (%) : 217
Market Place
Reply
25 Sep 2024
Reply
18 Jan 2024
Patents & EXCLUSIVITIES
Patent Expiration Date : 2028-12-04
US Patent Number : 8828956
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214012
Patent Use Code : U-3652
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-12-04
Patent Expiration Date : 2027-05-10
US Patent Number : 8809292
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214012
Patent Use Code : U-3652
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-05-10
Patent Expiration Date : 2029-12-12
US Patent Number : 8106022
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214012
Patent Use Code : U-3652
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-12
Patent Expiration Date : 2028-08-24
US Patent Number : 10131907
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214012
Patent Use Code : U-3652
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-08-24
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?